Cargando…

Initiation of once daily insulin detemir is not associated with weight gain in patients with type 2 diabetes mellitus: results from an observational study

BACKGROUND: Obesity is common in type 2 diabetes (T2DM) and is associated with increased risk of morbidity and all-cause mortality. This analysis describes weight changes associated with insulin detemir initiation in real-life clinical practice. METHODS: Study of Once-Daily Levemir (SOLVE) was a 24-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yale, Jean-François, Damci, Taner, Kaiser, Marcel, Karnieli, Eddy, Khunti, Kamlesh, Liebl, Andreas, Baeres, Florian MM, Svendsen, Anne Louise, Ross, Stuart A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851763/ https://www.ncbi.nlm.nih.gov/pubmed/24499517 http://dx.doi.org/10.1186/1758-5996-5-56

Ejemplares similares

Observational Study of Once-Daily Insulin Detemir in People with Type 2 Diabetes Aged 75 Years or Older: A Sub-Analysis of Data from the Study of Once-Daily Levemir (SOLVE)
por: Karnieli, Eddy, et al.
Publicado: (2013)

Lower risk of hypoglycaemia and greater odds for weight loss with initiation of insulin detemir compared with insulin glargine in Turkish patients with type 2 diabetes mellitus: local results of a multinational observational study
por: Damci, Taner, et al.
Publicado: (2014)

Detemir as a once-daily basal insulin in type 2 diabetes
por: Nelson, Scott E
Publicado: (2011)

Health Economic Evaluation of Type 2 Diabetes Mellitus: A Clinical Practice Focused Review
por: Liebl, Andreas, et al.
Publicado: (2015)

Comparison of Once- Versus Twice-Daily Administration of Insulin Detemir, Used With Mealtime Insulin Aspart, in Basal-Bolus Therapy for Type 1 Diabetes: Assessment of Detemir Administration in a Progressive Treat-To-Target Trial (ADAPT)
por: Le Floch, Jean-Pierre, et al.
Publicado: (2009)

Comparison of the Efficacy and Safety of Insulin Detemir Administered Once Daily According to Two Titration Algorithms (3-0-3 and 2-4-6-8) in Patients with Type 2 Diabetes Mellitus
por: Yu, Hea Min, et al.
Publicado: (2020)

Once-Weekly Exenatide Versus Once- or Twice-Daily Insulin Detemir: Randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas
por: Davies, Melanie, et al.
Publicado: (2013)

Introduction to Personalized Medicine in Diabetes Mellitus
por: Glauber, Harry S., et al.
Publicado: (2014)

A 24-Week, Randomized, Treat-to-Target Trial Comparing Initiation of Insulin Glargine Once-Daily With Insulin Detemir Twice-Daily in Patients With Type 2 Diabetes Inadequately Controlled on Oral Glucose-Lowering Drugs
por: Swinnen, Sanne G., et al.
Publicado: (2010)

A Comparative Analysis of Once-daily and Twice-daily Formulation of Tacrolimus in De Novo Kidney Transplant Recipients
por: Ferhatoglu, Murat Ferhat, et al.
Publicado: (2021)

Nicotinamide Effects Oxidative Burst Activity of Neutrophils in Patients with Poorly Controlled Type 2 Diabetes Mellitus
por: Osar, Zeynep, et al.
Publicado: (2004)

Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus
por: Petersen, Andreas B, et al.
Publicado: (2013)

Once-daily dosing of gentamicin.
por: Soper, D E
Publicado: (1998)

Insulin Detemir Causes Lesser Weight Gain in Comparison to Insulin Glargine: Role on Hypothalamic NPY and Galanin
por: Zafar, Mohammad Ishraq, et al.
Publicado: (2014)

Insulin detemir attenuates food intake, body weight gain and fat mass gain in diet-induced obese Sprague–Dawley rats
por: Rojas, J M, et al.
Publicado: (2011)

Patients' preferences for once‐daily oral versus once‐weekly injectable diabetes medications: The REVISE study
por: Boye, Kristina, et al.
Publicado: (2020)

Biphasic insulin aspart‐30 reduces glycemic variability to a greater degree than insulin detemir: A randomized controlled trial of once‐daily insulin regimens using continuous glucose monitoring
por: Tsujino, Daisuke, et al.
Publicado: (2017)

Comparison of a Multiple Daily Insulin Injection Regimen (Glargine or Detemir Once Daily Plus Prandial Insulin Aspart) and Continuous Subcutaneous Insulin Infusion (Aspart) in Short-Term Intensive Insulin Therapy for Poorly Controlled Type 2 Diabetes Patients
por: Lv, Wen-shan, et al.
Publicado: (2013)

Insulin Detemir Reduces Weight Gain as a Result of Reduced Food Intake in Patients With Type 1 Diabetes
por: Zachariah, Sunil, et al.
Publicado: (2011)

ONCE DAILY RISPERIDONE IN TREATMENT OF SCHIZOPHRENIA
por: Agarwal, Vivek, et al.
Publicado: (2001)

The Short-Term Cost-Effectiveness of Once-Daily Liraglutide Versus Once-Weekly Exenatide for the Treatment of Type 2 Diabetes Mellitus in the United States
por: Wang, Bruce, et al.
Publicado: (2015)

The Alteration of Aspart Insulin Pharmacodynamics When Mixed With Detemir Insulin
por: Cengiz, Eda, et al.
Publicado: (2012)

Comparison of Once-Daily Bromfenac 0.07% Versus Once-Daily Nepafenac 0.3% in Patients Undergoing Phacoemulsification
por: Toyos, Melissa M.
Publicado: (2019)

Model‐Informed Development and Registration of a Once‐Daily Regimen of Extended‐Release Tofacitinib
por: Lamba, M, et al.
Publicado: (2017)

Benefits of once-daily therapies in the treatment of hypertension
por: Flack, John M, et al.
Publicado: (2011)

ONCE DAILY LITHIUM IN THE PROPHYLAXIS OF MOOD DISORDERS
por: Mohan, Rajesh, et al.
Publicado: (1996)

Differential Effects of Adiposity on Pharmacodynamics of Basal Insulins NPH, Glargine, and Detemir in Type 2 Diabetes Mellitus
por: Porcellati, Francesca, et al.
Publicado: (2011)

Effects of Switching from Insulin Glargine or Detemir to Insulin Degludec in Patients with Type 1 Diabetes Mellitus
por: Kusunoki, Yoshiki, et al.
Publicado: (2013)

Assessment of efficacy and tolerability of once-daily extended release metformin in patients with type 2 diabetes mellitus
por: Levy, Juliana, et al.
Publicado: (2010)

Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin
por: Kapitza, C, et al.
Publicado: (2013)

Is once enough? Understanding the preferences of COPD and asthma patients for once- versus twice-daily treatment
por: Horne, Rob
Publicado: (2013)

Comparison of thrice daily biphasic human insulin (30/70) versus basal detemir & bolus aspart in patients with poorly controlled type 2 diabetes mellitus – A pilot study
por: Shanmugasundar, G., et al.
Publicado: (2012)

Treatment of Type 1 and Type 2 Diabetes Mellitus with Insulin Detemir, a Long-Acting Insulin Analog
por: Young, Jason R., et al.
Publicado: (2010)

Correction: Assessment of efficacy and tolerability of once-daily extended release metformin in patients with type 2 diabetes mellitus
por: Levy, Juliana, et al.
Publicado: (2010)

Once-daily treatment of ADHD with guanfacine: patient implications
por: Strange, Brandon C
Publicado: (2008)

The use of once-daily dosing of gentamicin in obstetrics and gynecology.
por: Wiesenfeld, H C, et al.
Publicado: (1998)

Once-daily transdermal rivastigmine in the treatment of Alzheimer’s disease
por: Wentrup, Andreas, et al.
Publicado: (2009)

Once-daily medications for the pharmacological management of ADHD in adults
por: Tcheremissine, Oleg V, et al.
Publicado: (2009)

Potential benefit of dolutegravir once daily: efficacy and safety
por: Fantauzzi, Alessandra, et al.
Publicado: (2013)

Update on once-daily zonisamide monotherapy in partial seizures
por: Afra, Pegah, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_j9s0mofcmp6msskeifaj3619gk